Study Links MS Drug Class to High Risk of Severe West Nile Virus

Date:

- Advertisement -


All drugs come with both benefits and risks.

For people with multiple sclerosis (MS) who take anti-CD20 therapies — which include ocrelizumab (Ocrevus), ofatumumab (Kesimpta), rituximab (Rituxan), and ublituximab (Briumvi) — the primary benefit is fewer relapses and less disability progression.

One potential downside is a higher risk of infection, especially over the long term, as noted in this NeurologyLive peer exchange.

Neuroinvasive West Nile Virus

Now a paper published in the journal Neurology finds that people with MS being treated with ocrelizumab could be as much as 258 times more likely than the average population to contract neuroinvasive West Nile virus.


- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

Popular

More like this
Related

No posts to display